title: [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (1)--Single oral and intravenous dose toxicity studies in rats].
abstract: A single oral dose toxicity study of Cefmatilen hydrochloride hydrate (S-1090) and a single intravenous dose toxicity study of its sodium salt (S-1090-Na) were conducted in rats. One dose level of 2000 mg potency/kg was set in both studies. Single oral dose toxicity study of S-1090 No deaths occurred. Diarrhea occurred on the dosing day and slightly soft feces lasted until 6 days after administration. These changes were considered to result from changes of intestinal flora induced by the antibiotic activity of S-1090. Reddish-brown feces (due to chelated products of S-1090 or its decomposition products with Fe3+ in the diet) were also observed until the next day after administration. Body weights increased favorably, and no S-1090-related pathological changes were observed. The oral lethal dose of S-1090 was estimated to be more than 2000 mg potency/kg. Single intravenous dose toxicity study of S-1090-Na No deaths occurred. The rats showed characteristic clinical signs such as hypoactivity, abnormal gait and hypopnea immediately after dosing, and some rats showed prone position or paleness of eyeballs and ear auricles in due course. These signs disappeared by 4 hr after administration. Slightly soft feces and reddish-brown feces were observed much the same as in the orally-treated rats. Body weights increased favorably. In the pathological examinations, slight cecal enlargement and increased basophilia, dilatation and calcification of the renal tubules in the kidney were observed. The intravenous lethal dose of S-1090-Na was estimated to be more than 2000 mg potency/kg.
authors.affiliation: Developmental Research Laboratories, Shionogi & Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Yahara
authors.forename: H
authors.initials: H
authors.lastname: Furukawa
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Nishimura
authors.forename: A
authors.initials: A
authors.lastname: Harihara
authors.forename: K
authors.initials: K
authors.lastname: Yabuuchi
authors.forename: H
authors.initials: H
authors.lastname: Miyauchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kii
authors.forename: Y
authors.initials: Y
authors.lastname: Muraoka
authors.forename: T
authors.initials: T
authors.lastname: Kitamura
authors.forename: I
authors.initials: I
authors.lastname: Kato
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002511:Cephalosporins / Q000008:administration & dosage / Q000633:toxicity*; D003967:Diarrhea / Q000139:chemically induced; D007275:Injections, Intravenous; D007422:Intestines / Q000382:microbiology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D002511:Cephalosporins; C419864:cefmatilen